



February 20, 2019

Company name: Mitsubishi Chemical Holdings Corporation
Representative: Hitoshi Ochi
Representative Corporate Executive Officer,
President & Chief Executive Officer
TSE code no.:4188, 1st section
Contact: Hajime Takasaka
Executive Officer,
General Manager,
Public Relations and Investor Relations Office
Tel: [+81] (0)3-6748-7120

Mitsubishi Tanabe Pharma Corporation Received Notice of Request for Arbitration

Mitsubishi Chemical Holdings Corporation's consolidated subsidiary, Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC"; Head office: Osaka; President and Representative Director : Masayuki Mitsuka) announced today that Novartis Pharma AG has filed a Request for Arbitration against MTPC.

Please refer to the attached press release for details.



February 20, 2019

Company name: Mitsubishi Tanabe Pharma Corporation
Representative: Masayuki Mitsuka
President and Representative Director
Code number: 4508, First Section, Tokyo Stock Exchange
Contact: Yoshifumi Mifune, General Manager,
Corporate Communications Department
(TEL: +81-6-6205-5211)

Mitsubishi Tanabe Pharma Received Notice of Request for Arbitration

Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC") today announced that Novartis Pharma AG has filed a Request for Arbitration against MTPC as follows.

1. Circumstances and Arbitration Claim

(1) Circumstances

Yoshitomi Pharmaceutical Industries, Ltd. (hereinafter, "Yoshitomi") signed a licensing agreement with Novartis Pharma AG (hereinafter, "Novartis") in September 1997 (hereinafter, the "Agreement"), and granted Novartis a worldwide development right (in Japan, a co-development right) and marketing rights to FTY720 (generic name: fingolimod hydrochloride), the world's first sphingosine 1-phosphate receptor modulator discovered through joint research with Tetsuro FUJITA, a Professor at Kyoto University, Taito Co., Ltd. (currently, Mitsui Sugar Co., Ltd.) and Yoshitomi. MTPC is a successor to Yoshitomi under the Agreement. On February 15, 2019, the International Chamber of Commerce (hereinafter, "ICC") notified MTPC that Novartis had filed a Request for Arbitration against MTPC, challenging the enforceability of certain provisions under the Agreement.

(2) Arbitration Claim

Novartis requests a declaration that MTPC is not entitled to certain royalties under the Agreement based on product sales in the United States, EU, and certain other countries.

2. Overview of Claimant

- (1) Name of Claimant: Novartis Pharma AG
- (2) Address of Headquarters: Lichtstrasse 35, 4056 Basel, Switzerland
- (3) CEO: Paul Hudson

3. Outlook

MTPC has examined the enforceability of the Agreement and believes that the Novartis royalty payment obligations at issue are enforceable and that Novartis should honor the Agreement. Therefore, MTPC will oppose Novartis' requested relief in the arbitration. The arbitration will be conducted in London, UK, in accordance with the ICC Rules of Arbitration.

MTPC will continue to strive to make appropriate disclosure as to this matter in accordance with the circumstances, and will provide updates on the impact, if any, of the arbitration on its business performance.

End